國家衛生研究院 NHRI:Item 3990099045/13019
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 854568      Online Users : 701
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/13019


    Title: Thiazolidinediones were associated with higher risk of cardiovascular events in patients with type 2 diabetes and liver cirrhosis
    Authors: Yen, FS;Wei, JC;Chiu, LT;Hsu, CC;Hou, MC;Hwu, CM
    Contributors: Institute of Population Health Sciences
    Abstract: BACKGROUND& AIMS: Type 2 diabetes mellitus (T2DM) management in patients with liver cirrhosis is complicated. No clinical trials have investigated appropriate antidiabetic drug use in these patients. This study compared the risks of all-cause mortality, major adverse cardiovascular events (MACE), and hepatic outcomes between patients with T2DM and cirrhosis using and not using thiazolidinedione (TZD). METHODS: We selected 1,705 propensity score-matched TZD users and nonusers from a Taiwan National Health Insurance Research Database cohort of T2DM patients with compensated cirrhosis between January 1, 2000, and December 31, 2012 and followed them until December 31, 2013. Cox proportional hazards models with robust sandwich standard error estimates were used to assess risks of investigated outcomes for TZD users. RESULTS: MACE incidence rates during follow-up were 2.14 and 1.30 per 100 patient-years for TZD users and nonusers, respectively (adjusted hazard ratio [aHR] 1.70; 95% confidence interval [CI], 1.32-2.19). On the basis of TZD use, the aHRs (95% CIs) for stroke, ischemic heart disease, and heart failure were 1.81 (1.28-2.55), 1.59 (1.03-2.44), and 2.09 (1.22-3.60), respectively. Compared with TZD nonusers, rosiglitazone users had significantly higher aHR [1.67 (1.26-2.20)] and pioglitazone users had no significant difference of aHR [1.12 (0.90-1.64)]. All-cause mortality, hepatocellular carcinoma, decompensated cirrhosis, and hepatic failure risks did not differ significantly between TZD users and nonusers. CONCLUSIONS: Compared with nonuser, TZD users demonstrated significantly higher MACE risks. Therefore, the risks of cardiovascular complications should be considered when prescribing TZDs to patients with T2DM and cirrhosis.
    Date: 2021-01
    Relation: Liver International. 2021 Jan;41(1):110-122.
    Link to: http://dx.doi.org/10.1111/liv.14714
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1478-3223&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000588198300001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85096654158
    Appears in Collections:[Chih-Cheng Hsu] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    PUB33124143.pdf15922KbAdobe PDF257View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback